Icon
+91 94997 68112
Login Register

FLOVENT HFA - (0.044,0.11,0.22 mg/INH;Aerosol,Metered,Inhalation)

FLUTICASONE PROPIONATE GlaxoSmithkline
0.044,0.11,0.22 mg/INH;Aerosol,Metered,Inhalation
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
None None
Used to treat asthma in patients 4 years and older.
Yes
******* ** ******* ****** ** ********** ******* *** ****** *** ****** ****** ******** ** *** **, **** (*********). *** *** ** ******* *** ******** *** ** ***. **** ********** ******* (*** **, ****), ******* (*** **, ****) ** ******* ********** **** ** **** ** *** *** ********* ** ***. *** ** ****** **** ** *** ** ****** ** *** ****. ** *** **** ******* ** ****** ** ****, *** ******** *** ******* ********* ********, ** *** ****** ******* ***** *** **, ****.
FLOVENT HFA Patent 1 Patent 2 Patent 3 Patent 4
**** ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* *** *, **** ******* **** ***** *** ****
  1. *** **, **** : **** ******** *** ********* *** **** ** ****** **** ******* (*** **, ****), ******* (*** **, ****) ** *******.
  2. *** **, **** : *** **** **** ** ** ** ********.
  3. *** **, **** : ********** ********* **** ****, ***** *** ***** ** ********* *** *** *****.
  4. : ***** *** *** ***** ********* *** **** ******* ******** ** ********** ********.
  5. : **** *** ******** ** ****** * ******* ******* ** ******* *** *** ***/********** ** **** **** ********** ********** ** * ************** *****.

FLOVENT HFA - (0.22 mcg/inh ; Inhalation Aerosol)

FLUTICASONE PROPIONATE GlaxoSmithkline
0.22 mcg/inh ; Inhalation Aerosol
Less Than $1000 mn
None None
More Than 5
 None
None None
FLOVENT HFA Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adolescent and adult patients 12 years of age and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.
Yes
FLOVENT HFA Patent 1 Patent 2
** *******
  1. *** **, **** : * **** ** *** ***** *** ***** ** * *** *******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.